RFWD2通过介导多发性骨髓瘤中的P27泛素化来诱导细胞增殖和选择性蛋白酶体抑制剂抗性。 - Suppr

RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma.

作者信息

Gu Chunyan, Lu Ting, Wang Wang, Shao Miaomiao, Wei Rongfang, Guo Mengjie, Li Rui, Qiao Li, Hu Ye, Zhan Fenghuang, Seckinger Anja, Hose Dirk, Yang Ye

机构信息

The Third Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing, China.

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.

出版信息

Leukemia. 2021 Jun;35(6):1803-1807. doi: 10.1038/s41375-020-01033-z. Epub 2020 Sep 8.

DOI:10.1038/s41375-020-01033-z

PMID:32901100

Abstract

摘要

相似文献

RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma.RFWD2通过介导多发性骨髓瘤中的P27泛素化来诱导细胞增殖和选择性蛋白酶体抑制剂抗性。

Leukemia. 2021 Jun;35(6):1803-1807. doi: 10.1038/s41375-020-01033-z. Epub 2020 Sep 8.

ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.ZHX2 通过调节 NF-κB 的核转位介导多发性骨髓瘤对蛋白酶体抑制剂的耐药性。

Cancer Med. 2020 Oct;9(19):7244-7252. doi: 10.1002/cam4.3347. Epub 2020 Aug 11.

Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.蛋白酶体抑制剂诱导 SIRT1 去乙酰化 GLI2 以增强多发性骨髓瘤中的 hedgehog 信号转导活性和耐药性。

Oncogene. 2020 Jan;39(4):922-934. doi: 10.1038/s41388-019-1037-6. Epub 2019 Oct 1.

Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.cIAP2介导的多发性骨髓瘤对蛋白酶体抑制剂耐药性增加——联合治疗的意义

Oncotarget. 2015 Aug 21;6(24):20621-35. doi: 10.18632/oncotarget.4139.

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.通过抑制鞘氨醇激酶2使蛋白酶体抑制剂耐药的骨髓瘤重新敏感化。

Neoplasia. 2022 Jan;24(1):1-11. doi: 10.1016/j.neo.2021.11.009. Epub 2021 Nov 23.

Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.长链非编码 RNA NEAT1/miR-29b-3p/Sp1 形成正反馈回路，调节人多发性骨髓瘤细胞对硼替佐米的耐药性。

Eur J Pharmacol. 2021 Jan 15;891:173752. doi: 10.1016/j.ejphar.2020.173752. Epub 2020 Nov 28.

Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.蛋白质组学分析确定了通过靶向泛素受体 Rpn13 克服硼替佐米耐药的机制。

Leukemia. 2021 Feb;35(2):550-561. doi: 10.1038/s41375-020-0865-2. Epub 2020 May 18.

P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.P-糖蛋白抑制使人类乳腺癌细胞对蛋白酶体抑制剂敏感。

J Cell Biochem. 2017 May;118(5):1239-1248. doi: 10.1002/jcb.25783. Epub 2017 Jan 10.

β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.β-连环蛋白抑制剂 BC2059 作为单药治疗或与蛋白酶体抑制剂硼替佐米联合治疗多发性骨髓瘤有效。

Mol Cancer Ther. 2017 Sep;16(9):1765-1778. doi: 10.1158/1535-7163.MCT-16-0624. Epub 2017 May 12.

Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.靶向磷酸化 MARCKS 可克服耐药性并在多发性骨髓瘤的临床前模型中诱导抗肿瘤活性。

Leukemia. 2015 Mar;29(3):715-26. doi: 10.1038/leu.2014.255. Epub 2014 Sep 2.

引用本文的文献

DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis.DEK通过调节铁死亡促进多发性骨髓瘤对硼替佐米的耐药性。

Clin Exp Med. 2025 Jul 17;25(1):252. doi: 10.1007/s10238-025-01673-4.

Systematic Analysis of E3 Ligase-Related Genes Identified UBE2L3 as a Prognostic Biomarker Associated With Drug Resistance in Acute Myeloid Leukemia.E3 泛素连接酶相关基因的系统分析确定 UBE2L3 为急性髓系白血病中与耐药相关的预后生物标志物。

Int J Gen Med. 2025 Jan 29;18:459-472. doi: 10.2147/IJGM.S502644. eCollection 2025.

CUL4A-DDB1-circRFWD2 E3 ligase complex mediates the ubiquitination of p27 to promote multiple myeloma proliferation.CUL4A-DDB1-circRFWD2 E3 连接酶复合物介导 p27 的泛素化以促进多发性骨髓瘤增殖。

Exp Hematol Oncol. 2024 Nov 22;13(1):116. doi: 10.1186/s40164-024-00582-8.

Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.多发性骨髓瘤获得硼替佐米耐药：从机制到策略。

Curr Treat Options Oncol. 2024 Nov;25(11):1354-1365. doi: 10.1007/s11864-024-01273-6. Epub 2024 Oct 21.

STK40 inhibits trophoblast fusion by mediating COP1 ubiquitination to degrade P57.STK40 通过介导 COP1 泛素化降解 P57 抑制滋养细胞融合。

J Transl Med. 2024 Sep 20;22(1):852. doi: 10.1186/s12967-024-05360-y.

NAT10 promotes cell proliferation by acetylating mRNA to enhance translation efficiency in multiple myeloma.NAT10通过使mRNA乙酰化以提高多发性骨髓瘤中的翻译效率来促进细胞增殖。

Acta Pharm Sin B. 2022 Aug;12(8):3313-3325. doi: 10.1016/j.apsb.2022.01.015. Epub 2022 Jan 29.

AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.AHSA1 是多发性骨髓瘤细胞增殖和蛋白酶体抑制剂耐药性的一个有前途的治疗靶点。

J Exp Clin Cancer Res. 2022 Jan 6;41(1):11. doi: 10.1186/s13046-021-02220-1.

Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma Mice Decreasing Metabolic Ornithine.针刺联合硼替佐米可提高多发性骨髓瘤小鼠的生存率并降低代谢性鸟氨酸水平

Front Oncol. 2021 Nov 2;11:779562. doi: 10.3389/fonc.2021.779562. eCollection 2021.

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma.CHEK1 和 circCHEK1_246aa 引发多发性骨髓瘤中的染色体不稳定性并诱导骨病变形成。

Mol Cancer. 2021 Jun 5;20(1):84. doi: 10.1186/s12943-021-01380-0.

Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma.靶向RFWD2作为抑制多发性骨髓瘤细胞增殖和克服对蛋白酶体抑制剂耐药性的有效策略。

Front Cell Dev Biol. 2021 Apr 21;9:675939. doi: 10.3389/fcell.2021.675939. eCollection 2021.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献